CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience Minimalist transcatheter aortic valve replacement: The new standard for surgeons and cardiologists using transfemoral access? 2019 ACC/AHA/ASE Advanced Training Statement on Echocardiography (Revision of the 2003 ACC/AHA Clinical Competence Statement on Echocardiography): A Report of the ACC Competency Management Committee Systemic microvascular dysfunction in microvascular and vasospastic angina Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Subgroup Analysis From ULTIMATE Trial A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Extreme Levels of Air Pollution Associated With Changes in Biomarkers of Atherosclerotic Plaque Vulnerability and Thrombogenicity in Healthy Adults Poor Long-Term Survival in Patients With Moderate Aortic Stenosis Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy
|<<... 90 91 92 93 94 95 96 ...>>|

Clinical Trial2017 Apr 18;69(15):1913-1920.

JOURNAL：J Am Coll Cardiol. Article Link

Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction

Pöss J, Köster J, Fuernau G et al. Keywords: TIMI flow grade; acute coronary syndrome; mortality; percutaneous coronary intervention; prognosis; risk score; IABP-SHOCK II trial

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top